BLIN, MD, PhD, MBA
Olivier BLIN (MD, PhD, MBA), 58 yo, is Professor of Pharmacology at Aix-Marseille University, certified in Neurology, Psychiatry and Medical Biology. He owns a PhD in Human Biology as well as a MBA from Ecole Centrale Paris.
He is currently Head of the Clinical Pharmacology & Pharmacovigilance Department, Marseille University Hospital (Ap-Hm), member of UMR AMU-INSERM 1106, and coordinator of the University Hospital Federation DHUNE, COEN center on neurodegenerative disorders and aging (www.dhune.org).
At the national level, he is a Member of the Working Group French National Plan for Rare Diseases, Member of the National Steering Committee French National Plan for Neurodegenerative Diseases and of the scientific committee of CNS ITMO Aviesan. He also is Vice President of the scientific council of CSFRS (Ecole Militaire, Paris).
At the international level, he has been elected as a member of Innovative Medicines Initiative Scientific Council by the 28 EU members. IMI is the world’s biggest public-private partnership (PPP) in the life sciences (€3.3 billion budget for the period 2014-2020) that aims to improve health by speeding up the development of, and patient access to, innovative medicines. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA).
Olivier Blin is a Past member of the Board of the French Minister of Health (2004-05), Founding Vice-President of Eurobiomed Cluster, Past Head of Unit Physician, CNS, GSK, Shanghai (2011-13) and Past Visiting Professor at Imperial College London (2012-13).
His main achievements include the following:
i) to have conducted and signed the report of clinical studies (Marketing Authorization dossier) of 15 drugs,
ii) to have initiated in France the Cengeps (90 million € contribution (2005-2015) of the pharmaceutical industry to academic clinical research)
iii) to have developed the collaboration between French and Indian on behalf of the French Minister of Industry (2010), and coordinated the New Indigo FP7 AlzBioIndigo project;
iv) to have initiated and coordinated the IMI PharmaCog project (2010-15), a 27 M€ public private partnership aiming to “predict the cognitive properties of new drug candidates for Alzheimer’s Disease”
v) to regularly contribute to the EMA forums and guidelines revision on NDDs (2014)
vi) to contribute with DHUNE and participate to the RHUS Epinov project (2018-2022), a 18 M€ public private partnership aiming at improving epilepsy management using brain modeling technology (the Virtual Brain).
Olivier Blin authored more than 270 scientific papers (available on PubMed) with H google index: 49
Clinical trials consulting DHUNE